# The ANC Study Group on Health welcomes the South African Health Products Regulatory Authority’s approval of the registration of lenacapavir. This is a new, groundbreaking HIV-prevention drug that only needs to be taken twice a year. South Africa is the first country in Africa to approve lenacapavir. The ANC says this milestone marks a significant step forward in expanding HIV-prevention options and demonstrates South Africa’s leadership in the global HIV response. It adds that this also reaffirms the country’s readiness to scale up equitable access to new long-acting HIV-prevention technologies.
ANC Study Group on Health welcomes approval of new injectable HIV prevention drug